Shanghai Henlius Biotech, Organon announce FDA acceptance of BLA for HLX14

The BLA filing is supported by data from a series of head-to-head studies for HLX14, which include comparative quality analytical studies and two clinical trials. Credit: Louis Reed on Unsplash.